U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

The health-care sector has been rebounding recently following a sharp selloff in recent weeks amid hopes that controversy would die down. The health-care industry group was among the leading S&P 500 ...

after scrapping a twice- daily version of the drug late last year. Pfizer moves forward with once-daily weight-loss pill Future of Healthcategory· July 11, 2024 U.S. President Joe Biden and ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they really work? Zoë Beaty looks at how the health landscape is rapidly changing to ...

Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Pfizer’s drug becomes an option for young people with ... loss of appetite, and weight loss, said Pfizer. “Today’s guidance is a step forward for eligible patients, giving them access ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...